Iowa Mutation Modeling Program
Iowa Mutation Modeling Program
Mutation: Aβ Asp23Asn Objective: Determine whether mutation-specific changes in aggregation kinetics are sufficient to explain altered amyloid deposition patterns and clinical onset timing.
1. Biological Background
1.1 Genetic and Molecular Context
- Description of the Asp23Asn substitution
- Location within Aβ sequence
- Known biochemical effects (e.g., altered charge, isomerization propensity)
1.2 Reported Phenotypic Features
- Age of onset distribution
- Neuropathological characteristics
- Reported fibril properties
- Relevant clinical observations
2. Working Mechanistic Hypothesis
Precise statement of the causal claim under investigation.
Example structure:
- The Asp23Asn mutation alters local electrostatic interactions.
- This increases fibril thermodynamic stability.
- Increased stability modifies aggregation kinetics (nucleation, elongation, secondary nucleation).
- Altered kinetics propagate to macroscopic plaque accumulation dynamics.
Clearly distinguish:
- Assumptions
- Empirical constraints
- Open uncertainties
3. Mathematical Formalization
3.1 Aggregation Kinetics Model
- Governing equations (e.g., nucleation–elongation framework)
- Definition of state variables
- Rate constants
- Conservation constraints
3.2 Mutation-Specific Modifications
- Which parameters differ from wild-type?
- Justification for parameter changes
- Sensitivity to parameter variation
3.3 Assumptions and Simplifications
- Spatial homogeneity vs heterogeneity
- Deterministic vs stochastic treatment
- Boundary conditions
4. Parameterization
Structured parameter table:
| Parameter | Symbol | Value | Source | Experimental Context |
|---|---|---|---|---|
| Primary nucleation rate | k_n | ... | ... | in vitro aggregation assay |
| Elongation rate | k_+ | ... | ... | ... |
| Secondary nucleation rate | k_2 | ... | ... | ... |
Include:
- Units
- Measurement uncertainty
- Scaling assumptions (in vitro → in vivo)
5. Scaling Strategy
How molecular kinetics propagate upward.
5.1 From Aggregates to Plaque Load
- Mapping monomer/polymer concentration to plaque mass
- Spatial assumptions
5.2 From Plaque Load to Imaging Signal
- Relationship to PET SUVR
- Assumed conversion functions
5.3 From Plaque Accumulation to Clinical Onset
- Threshold hypotheses
- Network vulnerability assumptions
Explicitly state which links are empirical vs theoretical.
6. Quantitative Predictions
Clearly enumerated, falsifiable predictions:
- Predicted shift in age of detectable amyloid PET signal
- Predicted plaque growth rate differences vs wild-type
- Predicted regional deposition differences
- Sensitivity of onset timing to kinetic parameters
Avoid vague language. Use numerical ranges where possible.
7. Comparison with Existing Data
- PET studies in Iowa mutation carriers
- Reported onset ages
- Neuropathological findings
Explicitly state:
- Agreement
- Discrepancies
- Unexplained features
8. Sensitivity and Identifiability Analysis
- Which parameters dominate model behavior?
- Are multiple parameter combinations indistinguishable?
- Which measurements would most constrain uncertainty?
This section signals modeling seriousness.
9. Open Problems
- Missing kinetic measurements
- In vivo vs in vitro scaling uncertainties
- Spatial heterogeneity
- Interaction with tau pathology
10. Next Steps
- Required data
- Computational refinement
- Proposed experimental collaborations